Vol. 3 No. 1 (2023)
Reimbursement Reviews

Cabozantinib (Cabometyx)

decorative image

Published January 24, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cabozantinib (Cabometyx), tablets, 20 mg, 40 mg, 60 mg oral.
  • Indication: For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.